UBS Group
BOLT icon

UBS Group’s Bolt Biotherapeutics BOLT Stock Holding History

UBS Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$982 Sell
255
-532
-68% -$2.5K ﹤0.01% 9675
2026
Q1 		$3.18K Buy
787
+272
+53% +$1.42K ﹤0.01% 9128
2025
Q4 		$2.82K Buy
515
+512
+17,067% +$2.75K ﹤0.01% 9216
2025
Q3 		$16 Sell
3
-180
-98% -$998 ﹤0.01% 10157
2025
Q2 		$1.06K Sell
183
-5,392
-97% -$35.7K ﹤0.01% 9678
2025
Q1 		$44.6K Buy
5,575
+2,269
+69% +$21.8K ﹤0.01% 7677
2024
Q4 		$35.4K Buy
3,306
+1,541
+87% +$18.6K ﹤0.01% 7509
2024
Q3 		$22.9K Sell
1,765
-676
-28% -$9.32K ﹤0.01% 7289
2024
Q2 		$36.6K Buy
2,441
+1,832
+301% +$36.1K ﹤0.01% 6927
2024
Q1 		$17K Buy
609
+226
+59% +$5.23K ﹤0.01% 6993
2023
Q4 		$8.57K Buy
383
+379
+9,475% +$7.38K ﹤0.01% 7541
2023
Q3 		$89 Buy
+4
New +$98 ﹤0.01% 8911
2022
Q3 		– Sell
-126
Closed -$5K – 10344
2022
Q2 		$5K Buy
126
+47
+59% +$1.82K ﹤0.01% 8846
2022
Q1 		$4K Buy
79
+78
+7,800% +$5.25K ﹤0.01% 9273
2021
Q4 		$0 Sell
1
-12
-92% -$2.28K ﹤0.01% 10263
2021
Q3 		$3K Buy
+13
New +$3.67K ﹤0.01% 8794
2021
Q2 		– Sell
-23
Closed -$15K – 9393
2021
Q1 		$15K Buy
+23
New +$15K ﹤0.01% 7618

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's BOLT Position: Q2 2026 in Review

UBS Group reduced its Bolt Biotherapeutics (BOLT) stake by 68% in Q2 2026, selling an estimated $2.5K and leaving 255 shares worth $982. The position accounts for ﹤0.01% of the portfolio, ranked #9675.

UBS Group first reported a position in BOLT in Q1 2021 and has held it in 17 quarters since. The position peaked at $44.6K in Q1 2025. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • UBS Group held 255 shares of Bolt Biotherapeutics worth $982 as of Q2 2026.
  • UBS Group sold 532 Bolt Biotherapeutics shares in Q2 2026, an estimated $2.5K.
  • Bolt Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9675 holding.
  • UBS Group first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 17 quarters since.
  • UBS Group's Bolt Biotherapeutics position peaked at $44.6K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.